{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:18:30Z","timestamp":1791397110671,"version":"4.3.3"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s HORIZON-MISS-2022-CANCER-01-03","award":["101104574"],"award-info":[{"award-number":["101104574"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>At diagnosis, metastatic prostate cancer (PC) is sensitive to androgen deprivation therapy (ADT), and patients are usually referred to as having castration-sensitive prostate cancer (mCSPC). The combination of ADT and androgen receptor pathway inhibitors (ARPI) is the current standard of care for mCSPC. This study aimed to review the literature on economic evaluations and health economic models related to mCSPC. A literature search was performed covering Medline, Embase, and Scopus with additional grey literature sources. Studies with data on health economic evaluations focusing on Europe or North America were relevant. 18 peer-reviewed articles and 10 grey literature documents were included. The majority (n = 23) had a deterministic Markov structure and applied either Markov cohort or partitioned survival models. Evaluations investigated various types of ADT-based combinations, comparing the addition of ARPI, chemotherapy agents, or radiation therapy to ADT alone. We concluded that economic evaluations in the field of PC are widely published, and there are a large number of publications even in the specific subgroup of mCSPC. Regardless of the investigated interventions, most studies applied similar methodologies and simulated patients from the mCSPC state until the development of mCRPC or death.<\/jats:p>","DOI":"10.3390\/curroncol32080412","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:35:28Z","timestamp":1753191328000},"page":"412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic Literature Review on Economic Evaluations and Health Economic Models in Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.3390","volume":"32","author":[{"given":"Thanh Tu","family":"Nguyen","sequence":"first","affiliation":[{"name":"Center for Health Technology Assessment, Semmelweis University, 1091 Budapest, Hungary"},{"name":"Center for Pharmacology and Drug Research & Development, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3591-5372","authenticated-orcid":false,"given":"David","family":"Ameyaw","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"},{"name":"Syreon Research Africa, Accra F892\/1, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Dennis","family":"Obeng","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"},{"name":"Syreon Research Africa, Accra F892\/1, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Amuah","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"},{"name":"Syreon Research Africa, Accra F892\/1, Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"J\u00f3zwiak-Hagym\u00e1sy","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2891-5195","authenticated-orcid":false,"given":"Tam\u00e1s","family":"D\u00f3czi","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Mezei","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-5147","authenticated-orcid":false,"given":"Bertalan","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-1622","authenticated-orcid":false,"given":"Attila","family":"Tordai","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahu","family":"Alanya","sequence":"additional","affiliation":[{"name":"Quality of Life Department, European Organization for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2784-8576","authenticated-orcid":false,"given":"Guillaume","family":"Grisay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centres Hospitaliers Universitaires HELORA, 7100 La Louvi\u00e8re, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-639X","authenticated-orcid":false,"given":"Marcell","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Syreon Research Institute, 1145 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"European Cancer Information System (2024, October 22). Cancer Statistics. Available online: https:\/\/ecis.jrc.ec.europa.eu\/en."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","first-page":"100606","article-title":"Current status and future perspective on the management of metastatic castration-sensitive prostate cancer","volume":"32","author":"Blas","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.23.00723","article-title":"Early treatment intensification in metastatic hormone-sensitive prostate cancer","volume":"41","author":"Wala","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.21037\/tau-20-1118","article-title":"Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer\u2014A narrative review","volume":"10","author":"Ong","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/UPJ.0000000000000363","article-title":"The cost of metastatic prostate cancer in the United States","volume":"10","author":"Olsen","year":"2023","journal-title":"Urol. Pr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1476-5381.2009.00550.x","article-title":"Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development","volume":"159","author":"Bodrogi","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","unstructured":"Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., and Torrance, G.W. (2015). Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40259-023-00583-9","article-title":"Systematic literature review of economic evaluations of treatment alternatives in chronic lymphocytic leukemia","volume":"37","author":"Lorenzovici","year":"2023","journal-title":"BioDrugs"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chan, V.K.Y., Yang, R., Wong, I.C.K., and Li, X. (2022). Cost-effectiveness of poly ADP-ribose polymerase inhibitors in cancer treatment: A systematic review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.891149"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Grochtdreis, T., K\u00f6nig, H.H., Dobruschkin, A., von Amsberg, G., and Dams, J. (2018). Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208063"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jval.2021.08.010","article-title":"Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity","volume":"25","author":"Butala","year":"2022","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/14656566.2021.1925647","article-title":"A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer","volume":"22","author":"Moussa","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40273-017-0555-8","article-title":"Treatments for metastatic prostate cancer (mPC): A review of costing evidence","volume":"35","author":"Norum","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/erp.13.12","article-title":"Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer","volume":"13","author":"Hatoum","year":"2013","journal-title":"Expert. Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/11631390-000000000-00000","article-title":"Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours","volume":"30","author":"Carter","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clgc.2022.04.014","article-title":"Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations","volume":"20","author":"Bataillard","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol29050275","article-title":"The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer\u2014A Systematic Literature Review with Application to the Canadian Context","volume":"29","author":"Yanev","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: The ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2016","journal-title":"Expert. Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jval.2010.10.023","article-title":"Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy","volume":"14","author":"Iannazzo","year":"2011","journal-title":"Value Health"},{"key":"ref_25","first-page":"E418","article-title":"Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model","volume":"14","author":"Hird","year":"2020","journal-title":"J. Assoc. Med. Microbiol. Infect Dis. Can."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2033787","DOI":"10.1001\/jamanetworkopen.2020.33787","article-title":"Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer","volume":"4","author":"Ades","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1464-410X.2011.10434.x","article-title":"Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer","volume":"109","author":"Lu","year":"2012","journal-title":"BJU Int."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Barbier, M.C., Tomonaga, Y., Menges, D., Yebyo, H.G., Haile, S.R., Puhan, M.A., and Schwenkglenks, M. (2022). Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0277282"},{"key":"ref_29","first-page":"396","article-title":"Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer","volume":"13","author":"Beca","year":"2019","journal-title":"J. Assoc. Med. Microbiol. Infect Dis. Can."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"De Bleser, E., Willems, R., Decaestecker, K., Annemans, L., De Bruycker, A., Fonteyne, V., Lumen, N., Ameye, F., Billiet, I., and Joniau, S. (2020). A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 12.","DOI":"10.3390\/cancers12010132"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2020.06.009","article-title":"Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer","volume":"108","author":"Parikh","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_32","first-page":"E126","article-title":"A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer","volume":"16","author":"Parmar","year":"2022","journal-title":"J. Assoc. Med. Microbiol. Infect Dis. Can."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/j.clgc.2021.03.022","article-title":"Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer","volume":"19","author":"Schiele","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_34","first-page":"688","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13696998.2022.2066850","article-title":"Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada","volume":"25","author":"Saad","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sung, W.W., Choi, H.C., Luk, P.H., and So, T.H. (2021). A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.627083"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: A public-payer perspective","volume":"115","author":"Yoo","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2021.10.016","article-title":"Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis","volume":"25","author":"Wang","year":"2022","journal-title":"Value Health J. Int. Soc. Pharmacoecon. Outcomes Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhang, P.-F., Xie, D., and Li, Q. (2021). Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis. Front. Public. Heal, 9.","DOI":"10.3389\/fpubh.2021.608375"},{"key":"ref_41","first-page":"550","article-title":"Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta","volume":"41","year":"2017","journal-title":"Farm. Hosp."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jval.2023.03.353","article-title":"EE47 Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic CaFstration-Sensitive Prostate Cancer (MCSPC): A Partitioned-Survival Model","volume":"26","author":"Katta","year":"2023","journal-title":"Value Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jval.2023.09.1841","article-title":"HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)","volume":"26","author":"Madani","year":"2023","journal-title":"Value Health"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jval.2023.03.562","article-title":"EE261 Cost-Effectiveness of Adding Darolutamide to Docetaxel and Androgen Deprivation Therapy in the Treatment of Metastatic Hormone-Sensitive Prostrate Cancer","volume":"26","author":"Nwogu","year":"2023","journal-title":"Value Health"},{"key":"ref_45","unstructured":"National Institute for Health and Care Excellence (NICE) (2024, May 02). Darolutamide with Androgen Deprivation Therapy and Docetaxel for Treating Hormone-Sensitive Metastatic Prostate Cancer [TA903]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta903."},{"key":"ref_46","unstructured":"National Institute for Health and Care Excellence (NICE) (2024, May 02). Apalutamide with Androgen Deprivation Therapy for Treating Hormone-Sensitive Metastatic Prostate Cancer [TA741]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta741."},{"key":"ref_47","unstructured":"National Institute for Health and Care Excellence (NICE) (2024, May 02). Abiraterone for Treating Newly Diagnosed High-Risk Hormone-Sensitive Metastatic Prostate Cancer (TA721). Available online: https:\/\/www.nice.org.uk\/guidance\/ta721."},{"key":"ref_48","unstructured":"National Institute for Health and Care Excellence (NICE) (2024, May 02). Enzalutamide for Treating Hormone-Sensitive Metastatic Prostate Cancer [TA712]. Available online: https:\/\/www.nice.org.uk\/guidance\/ta712."},{"key":"ref_49","unstructured":"Canadian Agency for Drugs & Technologies in Health (CADTH) (2024, May 02). Darolutamide. Available online: https:\/\/www.cadth.ca\/darolutamide."},{"key":"ref_50","unstructured":"Canadian Agency for Drugs & Technologies in Health (CADTH) (2024, May 02). Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer\u2014Details. Available online: https:\/\/www.cadth.ca\/enzalutamide-xtandi-metastatic-castration-sensitive-prostate-cancer-details."},{"key":"ref_51","unstructured":"Canadian Agency for Drugs & Technologies in Health (CADTH) (2024, May 02). Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer\u2014Details. Available online: https:\/\/www.cadth.ca\/apalutamide-erleada-metastatic-castration-sensitive-prostate-cancer-details."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: A systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Grisay, G., Turco, F., Litiere, S., Fournier, B., Patrikidou, A., Gallardo, E., McDermott, R., Alanya, A., Gillessen, S., and Tombal, B. (2024). EORTC 2238 \u201cDe-Escalate\u201d: A pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1391825"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"oyaf095","DOI":"10.1093\/oncolo\/oyaf095","article-title":"Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: A cost-effectiveness focused review","volume":"30","author":"Rojas","year":"2025","journal-title":"Oncologist"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Ameyaw, D., Obeng, G.D., Amuah, R., J\u00f3zwiak-Hagym\u00e1sy, J., D\u00f3czi, T., Mezei, D., N\u00e9meth, B., Tordai, A., and Alanya, A. (2024, January 17\u201320). Systematic Literature Review on Economic Evaluations and Health Economic Models in the Field of Metastatic Castration-Sensitive Prostate Cancer. Proceedings of the Conference Poster Presented at ISPOR Europe 2024 Conference, Barcelona, Spain.","DOI":"10.1016\/j.jval.2024.10.3131"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0272989X231201621","article-title":"Cost-effectiveness analysis for therapy sequence in advanced cancer: A microsimulation approach with application to metastatic prostate cancer","volume":"43","author":"Handorf","year":"2023","journal-title":"Med. Decis. Mak."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.euo.2023.11.013","article-title":"Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?","volume":"7","author":"Sathianathen","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13014-024-02544-0","article-title":"Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective","volume":"19","author":"Kramer","year":"2024","journal-title":"Radiat. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:58Z","timestamp":1760033638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080412"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080412","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}